Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 537

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 537
---
ger, on January 14, 2025, Nasdaq granted Cara an extension until May 19, 2025 to regain compliance with the Stockholders’ Equity Requirement. The Merger will constitute a “change of control” for purposes of Nasdaq’s listing rules and will require that the combined company comply with all applicable criteria for initial listing on The Nasdaq Capital Market, including a higher minimum bid price requirement and higher minimum stockholders’ equity requirement. The parties intend to satisfy each of the applicable listing criteria upon completion of the proposed Merger such that the combined company will remain listed on The Nasdaq Capital Market.

While Cara is making every effort to regain compliance prior to the extended deadline, there can be no assurance that Cara will be able to regain compliance within the extension period, by consummation of the Merger or otherwise, or will otherwise be in compliance with other Nasdaq listing criteria, including remaining in compliance with the minimum bid price requirement.

#### Assignment of Cara’s New Lease
On September 26, 2024, Cara entered into a Consent to Lease Assignment and Amendment to Lease with the Landlord and an Assignment and Assumption of Lease Agreement, or the Assignment Agreements, in which Cara’s corporate lease, leasehold improvements, and other property and equipment from Cara’s corporate office were transferred to a third party on November 1, 2024 (see Note 17 of Cara’s Notes to Condensed Consolidated Financial Statements as of September 30, 2024, Commitments and Contingencies — Assignment of New Lease , included elsewhere in this proxy statement/prospectus).

<div align='center'>313</div>

TABLE OF CONTENTS

Cara’s Product Portfolio

| Product                                    | ​ | ​ | Indication                  | ​ | ​ | Status                                                                                        | ​ | ​ | Next Milestone | ​ | ​ | Commercialization Rights                           | ​ |
| KORSUVA (difelikefalin) injection/Kapruvia | ​ | ​ | Pruritus CKD — Hemodialysis | ​ | ​ | Approved in the U.S. (08/2021)                                                                
 Approved in EU incl. UK (04/2022)                                                             
 Approved in Japan (09/2023)                                                                   
 Other approvals: Switzerland, Canada, Singapore, Australia, Kuwait, Israel, UAE, Saudi Arabia | ​ | ​ | ​              | ​ | ​ | CSL Vifor (Worldwide excl. Japan and South Korea)* 
 Maruishi (Japan)